ArticleMuscle & nerve2021
Doctor-Should I get the COVID-19 vaccine? Infection and immunization in individuals with neuromuscular disorders.
Article in Muscle & nerve, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Immunoinformatic-driven design and evaluation of multi-epitope mRNA vaccine targeting HIV-1 gp120.Frontiers in immunology · 2025Article
- Hesitancy, reactogenicity and immunogenicity of the mRNA and whole-virus inactivated Covid-19 vaccines in pediatric neuromuscular diseases.Human vaccines & immunotherapeutics · 2023Article
- Knowledge and willingness to receive a COVID-19 vaccine: a survey from Anhui Province, China.Human vaccines & immunotherapeutics · 2022Article
- Review
- Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience.European journal of neurology · 2022Article
- Neuromuscular complications after COVID-19 vaccination: a series of eight patients.Acta neurologica Belgica · 2022Article
- Vaccination and immunotherapies in neuroimmunological diseases.Nature reviews. Neurology · 2022Review
- Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort.Neurology international · 2022Article
- Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis.Neuromuscular disorders : NMD · 2022Article
- COVID-19 and the peripheral nervous system. A 2-year review from the pandemic to the vaccine era.Journal of the peripheral nervous system : JPNS · 2022Review
- A Comprehensive Review of Neuromuscular Manifestations of COVID-19 and Management of Pre-Existing Neuromuscular Disorders in Children.Journal of clinical medicine · 2022Review
- The relationship between myasthenia gravis and COVID-19: a systematic review.The Egyptian journal of neurology, psychiatry and neurosurgery · 2022Review
- Early immunological responses to the mRNA SARS-CoV-2 vaccine in patients with neuromuscular disorders.Frontiers in immunology · 2022Article
- COVID-19 and Vaccination in the Setting of Neurologic Disease: An Emerging Issue in Neurology.Neurology · 2021Article
- Unmet needs on the management of COVID-19 vaccination in patients with neuromuscular disorders.Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology · 2021Article
- What the Aftermath of the Global Pandemic Will Mean for Neurologists.Neurology international · 2021Article
- Doctor-Should I get the COVID-19 vaccine? Infection and immunization in individuals with neuromuscular disorders.Muscle & nerve · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical course of neuromuscular disorders (NMDs) can be affected by infections, both in immunocompetent individuals, and in those with reduced immunocompetence due to immunosuppressive/immunomodulating therapies. Infections and immunizations may also trigger NMDs. There is a potential for reduced efficacy of immunizations in patients with reduced immunocompetence. The recent vaccination program for coronavirus disease-2019 (COVID-19) raises several questions regarding the safety and efficacy of this vaccine in individuals with NMDs. In this Practice Topic article, we address the role of vaccine-preventable infections in NMDs and the safety and efficacy of immunization in individuals with NMDs, with emphasis on vaccination against COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.